Q1. What are GLP-1 agonists?
GLP-1 agonists are medications such as tirzepatide and semaglutide, often known by brand names like Mounjaro, Ozempic, or Wegovy. They are prescribed for individuals with type 2 diabetes or to help with weight loss. These medicines work by slowing down the rate at which food leaves the stomach.
Q2: What is the concern regarding GLP-1 agonists and oral HRT?
Recent guidance suggests that GLP-1 agonist medications, such as Mounjaro, Wegovy, Ozempic, and Rybelsus, may reduce the absorption of oral progesterone, which is in some forms of HRT. This potential interaction is thought to be due to GLP-1 agonists slowing down gastric emptying. This could reduce protection of the womb lining (endometrium) and potentially increase the risk of abnormal bleeding and even endometrial cancer.
Q3: Which oral HRT medications are affected?
Examples of HRT that could be affected include Progesterone (also known as Utrogestran or micronized progesterone), Norethisterone, and Medroxyprogesterone (also known as Provera).
Q4: What should I do if I am taking oral HRT and a GLP-1 agonist (Mounjaro, Wegovy, Ozempic, or Rybelsus)?
If you are taking oral HRT and Mounjaro, Wegovy, Ozempic, or Rybelsus, please contact the surgery via our triage form. A GP will contact you to ensure you are adequately protected.
Q5: What are the safe treatment options available?
Safe treatment options include switching to a Mirena coil (IUS), using a combined HRT patch, or potentially increasing your oral progesterone dose.
Q6: What if I am already taking a non-oral HRT (e.g., patch, gel, vaginal progesterone, Mirena coil) and a GLP-1 agonist?
GLP-1 agonists only affect oral HRT. They will not affect non-oral HRT, such as patches, gels, vaginal progesterone, or the Mirena coil. Therefore, you do not need to make any changes or contact the surgery.